Profits from Teva's (TEVA 2.00%) flagship drug, Copaxone, may be in jeopardy. The company just lost a major court case, invalidating a key patent, that will allow generic versions of the multiple sclerosis drug to market by May 2014, a full 16 months early. In this video, Motley Fool health-care analyst David Williamson discusses just how much this compressed timeline is going to hurt Teva and what he'll be looking for with the company going forward.
Teva: Feeling the Weight of Generic Competition
By Dave Williamson – Jul 31, 2013 at 5:48PM
NYSE: TEVA
Teva Pharmaceutical Industries
Market Cap
$27B
Today's Change
(-2.00%) $0.49
Current Price
$23.97
Price as of November 7, 2025 at 4:00 PM ET
Teva facing generic competition 16 months early is definitely going to hurt.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid